SEC seeks more time to analyse data on Covishield, Covaxin; next meet on Friday
- Serum Institute's proposal taken up on day when UK MHRA gives emergency authorisation to AstraZeneca vaccine
- AstraZeneca-Serum vaccine is one of the most significant so far in the global fight against covid-19 as it will be priced as little as $3 per dose
On a day when the UK regulator gave an emergency authorisation to AstraZeneca's covid-19 vaccine, an subject expert committee in India on Wednesday sought more time to analyse the additional data given by Serum Institute of India and Bharat Biotech International while seeking emergency licensure for their covid-19 vaccines, the health ministry said in a statement on Wednesday.
Login to enjoy exclusive benefits!
- Unlocked premium articles
- Personalized news
- Market Watchlist
- Insightful Newsletters & more